Status:

WITHDRAWN

Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

Lead Sponsor:

University of California, San Francisco

Conditions:

Lymphoma

Leukemia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The complex logistics and unique toxicities of chimeric antigen receptor T-cell (CAR-T) therapy require intensive patient education and careful monitoring. The Companion for CAR-T (CC) web app may be ...

Detailed Description

This is a single-arm pilot study assessing the feasibility and acceptability of the Companion for CAR-T (CC) web app among patients receiving commercially available CAR-T therapies. Primary Objective...

Eligibility Criteria

Inclusion

  • Diagnosis of a hematologic malignancy (including any plasma cell dyscrasia, any type of lymphoma, or any type of leukemia).
  • Planned receipt of an FDA-approved CAR-T therapy at University of California, San Francisco (UCSF) as standard of care.
  • Patient proficiency in spoken and written English.
  • Caregiver proficiency in spoken and written English.
  • Age \>= 18 years old

Exclusion

  • FDA-approved CAR-T therapy being administered as part of a prospective industry-sponsored trial, for example registrational trials of CAR-T therapy versus salvage chemotherapy or CAR-T therapy as an off-label line of therapy.
  • \*However, patients who receive an FDA-approved CAR-T therapy through an Expanded Access Program for non-conforming products (or any observational, non-interventional analysis of CAR-T products) are eligible.
  • Lack of ownership of a personal computing device, tablet device, or smartphone.
  • Refusal of patient and/or caregiver to sign up for a UCSF MyChart account.
  • \*Participants and caregivers who do not have a MyChart account at enrollment but are willing to create one will receive assistance from the study team to do so.
  • Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could - in the opinion of the study's Principal Investigator (PI) - interfere with provision of informed consent or compliance with study procedures.

Key Trial Info

Start Date :

January 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2025

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT05362331

Start Date

January 1 2023

End Date

June 30 2025

Last Update

February 9 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy | DecenTrialz